Critical Role for 24-Hydroxylation in Homeostatic Regulation of Vitamin D Metabolism

Zhinous Shahidzadeh Yazdi, Elizabeth A. Streeten, Hilary B. Whitlatch,

May E. Montasser, Amber L. Beitelshees, and Simeon I. Taylor

Department of Medicine

Division of Endocrinology, Diabetes, and Nutrition

University of Maryland School of Medicine

Baltimore, MD, USA

Corresponding author: Simeon I. Taylor, MD, PhD, Department of Medicine, University of

Maryland School of Medicine, Baltimore, MD 21201, USA

Telephone number: +1 301 980 5272

Email: staylor2@som.umaryland.edu

Conflict-of-interest statement: SIT serves as a consultant for Ionis Pharmaceuticals and receives
an inventor's share of royalties from NIDDK for metreleptin as a treatment for generalized
lipodystrophy. EAS, MEM, and HBW receive research support (unrelated to this project) from
the Regeneron Genetics Center. ZSY and ALB have no conflicts to disclose.

Trial registration: NCT02891954 (clinicaltrials.gov)

Funding: National Institute of Diabetes, Digestive, and Kidney Diseases: R01DK118942,
R01DK118924-02S1, and T32DK098107

Key words: vitamin D deficiency, 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, 25-
hydroxyvitamin D, parathyroid hormone, homeostatic regulation

ABSTRACT

Context. The body has evolved homeostatic mechanisms to maintain free levels of Ca^{+2} and 1,25-dihydroxyvitamin D [$1,25(OH)_2D$] within narrow physiological ranges. Clinical guidelines emphasize important contributions of PTH in maintaining this homeostasis.

Objective. To investigate mechanisms of homeostatic regulation of vitamin D (VitD) metabolism and to apply mechanistic insights to improve clinical assessment of VitD status.

Design. Crossover clinical trial studying participants before and after VitD3-supplementation.

Setting. Community.

Participants. 11 otherwise healthy individuals with VitD-deficiency (25-hydroxyvitamin D [$25(OH)D$] ≤ 20 ng/mL).

Interventions. VitD3-supplements (50,000 IU once or twice a week depending on BMI, for 4-6 weeks) were administered to achieve $25(OH)D \geq 30$ ng/mL.

Results. VitD3-supplementation significantly increased mean 25(OH)D by 2.7-fold and 24,25-dihydroxyvitamin D [$24,25(OH)_2D$] by 4.3-fold. In contrast, mean levels of PTH, FGF23, and $1,25(OH)_2D$ did not change in response to VitD3-supplementation. Mathematical modeling suggested that 24-hydroxylase activity was maximal for $25(OH)D \geq 50$ ng/mL and achieved a minimum (~90% suppression) with $25(OH)D < 10$-20 ng/mL. Suppression of 24-hydroxylase activity was triggered by mild-moderate VitD-deficiency, which sustains physiological levels of $1,25(OH)_2D$ by suppressing metabolic clearance of $1,25(OH)_2D$. VitD metabolite ratios [e.g., $1,25(OH)_2D/24,25(OH)_2D$] provide useful indices of VitD status. When VitD availability is limited, this suppresses 24-hydroxylase activity – thereby decreasing the level of $24,25(OH)_2D$

49   and increasing the $1,25(OH)_2D/24,25(OH)_2D$ ratio. Thus, a high $1,25(OH)_2D/24,25(OH)_2D$ ratio

50   signifies triggering of homeostatic regulation in response to mild-moderate VitD-deficiency.

51   *Conclusions*. Suppression of 24-hydroxylase activity provides a first line of defense against

52   symptomatic VitD-deficiency by decreasing metabolic clearance of $1,25(OH)_2D$. The

53    $1,25(OH)_2D/24,25(OH)_2D$ ratio can provide a useful index of clinical VitD status.

INTRODUCTION:

Vitamin D (VitD) plays an essential role in mediating absorption of dietary calcium in the intestine (1-4). Furthermore, as evidenced by diseases such as nutritional rickets, VitD is critical to maintaining bone health (5, 6). The body obtains VitD from two sources. Endogenous production of VitD requires exposure to ultraviolet light, which is variable depending on geographic location and the season of the year among other factors. Dietary intake of VitD is also variable and depends on the VitD content of the diet (including intake of fortified dairy products and dietary supplements) (7, 8). To maintain a consistent *milieu intérieure* (9, 10), each individual must maintain levels of free 1,25-dihydroxyvitamin D [$1,25(OH)_2D$] – the biologically active metabolite of VitD – within a narrow physiological range notwithstanding considerable variation in availability of the biosynthetic precursor (i.e., VitD) (11-13).

We developed a mathematical model to investigate physiological mechanisms mediating homeostatic regulation of VitD metabolism. 24-hydroxylation provides the major mechanism whereby $1,25(OH)_2D$ is cleared (12, 14, 15). According to our mathematical model, in vivo activity of 24-hydroxylase varies over an approximately tenfold range. 24-Hydroxylase activity achieves a maximum when 25(OH)D levels exceed 50 ng/mL. By inducing 24-hydroxylase activity when VitD is abundant, the body increases clearance of $1,25(OH)_2D$ – thereby protecting against VitD toxicity. 24-Hydroxylase activity achieves a minimum when 25(OH)D is less than 10-20 ng/mL. The resultant decrease in $1,25(OH)_2D$ clearance tends to sustain $1,25(OH)_2D$ levels, thereby compensating for limited availability of VitD and protecting against symptomatic VitD deficiency.

Several feedback loops contribute to homeostatic regulation of VitD – including feedback loops between VitD status and the rates of both production and clearance of $1,25(OH)_2D$ (12, 16-19).

Cannon proposed the concept of the "wisdom of the body" (9), which includes homeostatic

mechanisms that are responsible for maintaining a constant *milieu intérieure.* Endocrinologists

often leverage the "wisdom of the body" to diagnose states of hormonal excess or hormonal

insufficiency based on the level of activation or suppression of homeostatic mechanisms. This is

exemplified by the approach to diagnosing patients' hormonal status with respect to hormones

that act upon other nuclear hormone receptors (e.g., thyroid hormones or glucocorticoids) by

measuring the levels of trophic hormones (e.g., TSH or ACTH) (20, 21). By analogy, we discuss

our data in the context of the published literature advocating for a similar approach to assessing

VitD status – i.e., by assessing the level of suppression/induction of 24-hydroxylase activity (22-

24). By leveraging the wisdom of the body in this assessment, physicians can advance the state-

of-the-art of assessment of VitD status.

METHODS

This study ("VitD Sub-study") was part of our ongoing "Genetics of Response to Canagliflozin (GRC)" clinical trial (Clinicaltrials.gov Identifier: NCT02891954) in healthy volunteers recruited from the Old Order Amish population in Lancaster PA, who are non-Hispanic white people. Although participants were excluded from the parent study if their 25(OH)D level ≤20 ng/mL, these VitD deficient individuals were eligible to participate in the VitD Sub-study, which investigated the effects of VitD3 supplements on canagliflozin-triggered changes in the serum phosphorus/FGF23/1,25(OH)$_2$D/PTH axis (13). Participants were required to meet all other inclusion/exclusion criteria for the parent study. The effect of VitD3 supplementation on canagliflozin-induced changes in mineral metabolism biomarkers was reported elsewhere (13). The current paper reports results of a secondary data analysis focusing primarily on the effect VitD3 supplementation on VitD metabolites in participants with mild-moderate VitD deficiency.

Screening and recruitment:

As reported previously, we screened 24 healthy volunteers from September 2019 to July 2021 and enrolled 19 individuals with 25(OH)D levels ≤20 ng/mL who were otherwise eligible to participate in the parent GRC study (13). The Endocrine Society's clinical practice guidelines proposed thresholds of 25(OH)D ≤20 ng/mL (≤50 nmol/L) for VitD deficiency, 21-29 ng/mL (51-74 nmol/L) for VitD insufficiency, and ≥ 30 ng/mL (≥75 nmol/L) for VitD sufficiency (17). We applied The Endocrine Society's definition of VitD deficiency (≤20 ng/mL) as a key inclusion criterion for this sub-study and applied the definition of VitD sufficiency (≥30 ng/mL) as the criterion for adequacy of VitD3 supplementation. Details of demographics, baseline characteristics, recruitment, and disposition are reported elsewhere (13). Because of interruptions and delays associated with the COVID-19 pandemic, we did not complete our plan to study 25

research participants. We analyzed data after eleven participants (four females and seven males)

completed the entire study protocol.

Endpoints and biomarkers:

We measured levels of the following biomarkers both at baseline and after VitD3

supplementation: plasma PTH, plasma FGF23, serum phosphorus, serum calcium, and three

VitD metabolites – 25(OH)D, 1,25(OH)$_2$D, and 24,25-dihydroxyvitamin D [24,25(OH)$_2$D].

VitD3 supplementation protocol

VitD deficient participants completed canagliflozin challenge #1 and then received VitD3

capsules (Bio-Tech Pharmacal; Fayetteville, AR) in doses of either 50,000 IU per week for

participants with BMI <30 kg/m^2 or 50,000 IU twice a week for participants with BMI ≥30 kg/m

for four weeks, followed by a second total serum 25(OH)D measurement a week after

completion of the four-week VitD3 supplementation protocol (13). If screening serum 25(OH)D

levels (Quest Diagnostics) were <30 ng/mL, high-dose VitD3 supplementation was continued.

Once screening 25(OH)D (Quest Diagnostics) levels were confirmed to be ≥30 ng/mL,

maintenance-dose VitD3 supplementation (1000 IU/d or 2000 IU/d for BMI <30 kg/m^2 or BMI

≥30 kg/m^2, respectively) was continued until completion of canagliflozin challenge #2.

Clinical chemistry

Blood samples obtained at home visits were collected in test tubes as appropriate for each assay

(13). Quest Diagnostics conducted an immunoassay for baseline levels of plasma PTH as well as

LC-MS/MS assays to measure baseline serum 1,25(OH)$_2$D, and serum 25(OH)D levels. Plasma

levels of 25(OH)D and 24,25(OH)$_2$D were assessed using LC-MS/MS assays conducted by

Heartland Assays (Ames, IA). Quest's serum 25(OH)D levels were used to determine eligibility

for the VitD Sub-study. Heartland's plasma 25(OH)D levels were used to assess the response to

VitD3 supplements. We have reported 25(OH)D and 24,25(OH)$_2$D in ng/mL and 1,25(OH)$_2$D in

pg/mL. Multiplication by a factor of 2.49 can be used to convert from ng/mL to nmol/L. Mean

levels for 25(OH)D before and after VitD3 supplementation, were identical in assays conducted

by Quest Diagnostics and Heartland Assays (13). LC-MS/MS assays conducted at both Quest

Diagnostics and Heartland Assays distinguished between derivatives of VitD2 and VitD3.

Derivatives of VitD2 were not detected in any of our participants' samples. For simplicity, we

refer to our data on levels of 25(OH)D, 1,25(OH)$_2$D, or 24,25(OH)$_2$D without specifying D2 or

D3. Nevertheless, since D2 derivatives were not detected in any of our participants, this should

be understood as referring exclusively to D3 derivatives.

Quality control for VitD assays of VitD metabolites

Heartland Assays provided the following information regarding their assays of VitD metabolites:

25(OH)D and 24,25(OH)$_2$D. Accuracy >90% based on comparisons to National Institute of

Standards and Technology standards. Coefficients of variation for both inter- and intra-assay

were < 5%.

Analysis of our data. We obtained blood samples on three separate days during canagliflozin

(300 mg/day) challenge tests: baseline prior to receiving canagliflozin, at 48 hours (after

receiving canagliflozin for two days), and at 120 hours (after receiving canagliflozin for five

days). Because mean levels of 25(OH)D and 24,25(OH)$_2$D were not affected by canagliflozin,

we calculated coefficients of variation based on an assumption that the three separate blood

samples obtained from each individual during the canagliflozin challenge test had similar

concentrations of those two VitD metabolites. Based on this assumption, we calculated

coefficients of variation of 5.8% for 25(OH)D and 11.1% for 24,25(OH)$_2$D. Because these

calculated coefficients of variation included day-to-day variation in VitD metabolite levels as

well as intra-assay variation, our estimates of coefficients of variation are likely greater than the

actual intra-assay variation.

Furthermore, we compared mean data for 25(OH)D levels measured in the same individuals in

the two assays. Mean 25(OH)D levels before receiving VitD3 supplements were 16.4 and 16.5

ng/mL in the Quest and Heartland assays, respectively (13). Mean total 25(OH)D levels after

receiving VitD3 supplements were 45.3 and 44.3 ng/mL in the Quest and Heartland assays,

respectively (13). In addition, the individual data from the Quest assay (blood obtained on the

day of screening) was highly correlated with individual data from the Heartland assay (blood

obtained on Day 1 of the canagliflozin challenge test) – with variance in one assay accounting

for 81% of the variance in the other assay. Based on these data, we conclude that the two assays

provide comparable measurements of 25(OH)D levels. In any case, the Quest assay for 25(OH)D

was used only to determine eligibility for the study. The Heartland assay was the sole source of

data on 25(OH)D levels used for determination of goodness-of-fit for our model.

Published analysis of Quest's assay of 1,25(OH)$_2$D. Biancuzzo et al. (25) reported intra- and

inter-assay coefficients of variation of 9% and 12%, respectively, for Quest's assay of

1,25(OH)$_2$D. In addition, we estimated the inter-assay coefficient of variation based on our

observation that 1,25(OH)$_2$D levels were not changed by administration of VitD3 supplements.

When we calculated a coefficient of variation for 1,25(OH)$_2$D levels before and after VitD3

supplementation, we estimated a coefficient of variation of 13% – very similar to the inter-assay

coefficient of variation reported by Biancuzzo et al. (25). Our calculation of coefficient of

variation includes at least three components: the coefficient of variation for measurement error,

day-to-day variation, and a possible small effect of VitD3 supplementation on 1,25(OH)$_2$D

levels. Thus, our estimate of the coefficient of variation represents an upper bound for the actual

inter-assay coefficient of variation.

Mathematical Modeling

We developed a mathematical model to analyze relationships among 25(OH)D, 1,25(OH)$_2$D, and

24,25(OH)$_2$D. See Table 1 for definitions of model parameters. For the purpose of fitting curves

to model our clinical trial data, we estimated model parameters using an iterative trial and error

approach.

The observed sigmoid curve expressing the concentration of total 24,25(OH)$_2$D as a function of

total 25(OH)D was fitted by an equation with the form of Equation (1):

$$(1) \quad S(24,25) = \frac{(\frac{W24}{L24})e^{aS(25)}}{1+\frac{e^{aS(25)}}{L24}}$$

where S(25) and S(24,25) represent levels of 25(OH)D and 24,25(OH)$_2$D, respectively; W_{24} and

L_{24} represent analogs of the maximal velocity and Michaelis-Menten constant for 24-

hydroxylase enzyme, respectively, with 25(OH)D as substrate; α is a model parameter to

facilitate fitting the equation to the observed data.

The model assumes that 24,25(OH)$_2$D is cleared by a first order process with a rate constant of

m(24,25) [Equation (1a)]:

$$(1a) \ \textit{Rate of clearance of } 24,25(OH)_2D = m(24,25)\frac{(\frac{W24}{L24})e^{aS(25)}}{1+\frac{e^{aS(25)}}{L24}}$$

We hypothesized that the 24-hydroxylase enzyme follows Michaelis-Menten kinetics as

described by Equation (2):

$(2)\ Production\ of\ 24,25(OH)_2D = \dfrac{V24 \times h \times S(25)}{K24 + S(25)}$

where S(25) represents the level of 25(OH)D; V_{24} and K_{24} represent the maximal velocity and

Michaelis-Menten constant for 24-hydroxylase enzyme, respectively, with 25(OH)D as substrate.

h is a variable function of S(25) that represents 24-hydroxylase activity as a fraction of the

maximally induced level of the enzyme observed when 25(OH)D levels are high.

At steady state, the rate of production of 24,25(OH)$_2$D [Equation (2)] is equal to the rate at which

24,25(OH)$_2$D is cleared [Equation (1a)]. Accordingly, the value of h can be calculated by

Equation (3):

$(3)\ h = m(24,25)\ \dfrac{(\frac{W24}{L24})e^{aS(25)}}{1 + \frac{e^{aS(25)}}{L24}}\ \div\ \dfrac{V24 \times S(25)}{K24 + S(25)}$

Genetic evidence demonstrates the critical role of CYP24A1-mediated 24-hydroxylation in

inactivation of 1,25(OH)$_2$D (26, 27). Homozygosity for loss of function mutations in *CYP24A1*

has been reported to cause hypercalcemia – presumably due to excessive levels of 1,25(OH)$_2$D.

Since CYP24A1 catalyzes 24-hydroxylation of both 25(OH)D and 1,25(OH)$_2$D, we modified

Equation (1a) to yield Equation (4):

$(4)\ Rate\ of\ clearance\ of\ 1,25(OH)_2D = m(1,25)\ \dfrac{(\frac{W1,25}{L1,25})e^{aS(1,25)}}{1 + \frac{e^{aS(1,25)}}{L1,25}}$

where *S(1,25)* represents the level of 1,25(OH)$_2$D; $W_{1,25}$ and $L_{1,25}$ represent analogs of the

maximal velocity and Michaelis-Menten constant for 24-hydroxylase enzyme, respectively, with

1,25(OH)$_2$D as substrate; α is a model parameter that facilitates fitting the equation to the

observed data; and *m(1,25)* is a first-order rate constant analogous to *m(24,25)* in Equation (1a).

Further, we hypothesize that CYP27B1-mediated 1α-hydroxylation of 25(OH)D follows

Michaelis-Menten kinetics:

(5) $Production\ of\ 1,25(OH)_2D = \frac{V1 \times S(25)}{K1+S(25)}$

where V_1 and K_1 represent the maximal velocity and Michaelis-Menten constant for 1α-

hydroxylase, respectively, with 25(OH)D as substrate. Under steady state conditions, the rates of

production and metabolic clearance of 1,25(OH)$_2$D are equal. Thus, we can combine Equations

(4) and (5) to yield Equation (6):

(6) $\frac{V1 \times S(25)}{K1+S(25)} = m(1,25)\frac{(\frac{W_{1,25}}{L_{1,25}})e^{aS(1,25)}}{1+\frac{e^{aS(1,25)}}{L_{1,25}}}$

Solving for $S(1,25)$, we obtain Equation (7):

(7) $S(1,25) = \{Ln[S(25)] - Ln\left[m_{1,25} + \frac{S(25)}{K_1}\left(m_{1,25} - \frac{V_1}{W_{1,25}}\right)\right] - Ln\frac{W_{1,25}K_1}{L_{1,25}V_1}\}/a$

Goodness of fit

We calculated the following metrics in order to evaluate the goodness of fit between our

mathematical model and the experimental data:

Sum of squares due to regression: $\textbf{SSR} = \sum(\hat{x}_i - \bar{x})^2$

Total sum of squares about the mean: $\textbf{SST} = \sum(x_i - \bar{x})^2$

Sum of squared errors: $\textbf{SSE} = \sum(x_i - \hat{x}_i)^2$

Data on goodness of fit is provided in the Results section as appropriate.

Estimating relative 24-hydroxylase activity

Equation (3) expresses relative 24-hydroxylase activity (h) as a function of the 25(OH)D level.

However, total 25(OH)D levels are affected by inter-individual variation in VDBP levels, a

factor which is not included in our model. Accordingly, we replaced 25(OH)D levels by the ratio

of 25(OH)D/1,25(OH)$_2$D. The 25(OH)D/1,25(OH)$_2$D ratio is independent of VDBP level and

provides an index of free levels of 25(OH)D. To normalize values of this ratio to correspond to

values of total 25(OH)D, we first divided individual values of the 25(OH)D/1,25(OH)$_2$D by a

normalization factor [the mean value of the 25(OH)D/1,25(OH)$_2$D ratio before administration of

VitD3 supplements]. We next converted individual values of the normalized

25(OH)D/1,25(OH)$_2$D ratio to the same units as total 25(OH)D by multiplying by a conversion

factor [the mean value of 25(OH)D before administration of VitD3 supplements].

Statistics

A two-sided p-value <0.05 (paired t-test) was taken as the threshold for statistical significance

without any correction for multiple comparisons. We pooled all the data before and after VitD3

supplementation for graphing total levels of 1,25(OH)$_2$D and 24,25(OH)$_2$D as a function of total

levels of 25(OH)D. Both Pearson and Spearman correlation coefficients were calculated using

software provided in Excel.

Study approval

The Clinical Trial Protocol was approved by the University of Maryland Baltimore Institutional

Review Board (FWA00007145). Informed consent was obtained from all participants.

RESULTS

Herein we report results of a secondary analysis of data obtained in our published clinical trial investigating pharmacodynamic nutrient-drug interactions between VitD and canagliflozin (13). We applied mathematical modeling to investigate the effects of VitD3 supplementation on homeostatic regulation of VitD metabolite levels. The details of the mathematical model are summarized in the Methods section.

Interrelationships among $1,25(OH)_2D$, $24,25(OH)_2D$, and $25(OH)D$.

As reported previously, mean ($\pm$SEM) total plasma levels of both $25(OH)D$ and $24,25(OH)_2D$ increased significantly in response to VitD3 supplementation: from 16.5 ± 1.6 to 44.3 ± 5.5 ng/mL (p=0.0006) for $25(OH)D$ and from 1.0 ± 0.1 to 4.3 ± 0.6 ng/mL (p=0.0002) for $24,25(OH)_2D$ (13). We observed consistent increases in total levels of $25(OH)D$ and $24,25(OH)_2D$ (Figs. 1A and 1B). In contrast, mean total plasma levels of $1,25(OH)_2D$ did not change in response to VitD3 supplements (43.8 ± 3.6 pg/mL versus 44.9 ± 4.1 pg/mL; p=0.7) (Fig. 1C) (13). This observation provides strong evidence of the effectiveness of homeostatic mechanisms regulating levels of $1,25(OH)_2D$. Therefore, we conducted exploratory analyses to further investigate physiological mechanisms mediating this homeostatic regulation.

For this analysis, we pooled data on VitD metabolites – including data obtained both before and after VitD3 supplementation (Fig. 2). Although there was no significant correlation between total plasma levels of $1,25(OH)_2D$ and $25(OH)D$ (Fig. 2A), total plasma levels of $24,25(OH)_2D$ increased as a function of total plasma $25(OH)D$ levels (Fig. 2B).

A critical role for regulation of 24-hydroxylase activity in homeostatic regulation of $1,25(OH)_2D$

We considered possible mechanisms that might contribute to the observed sigmoid shape of the

curve relating total $24,25(OH)_2D$ levels to total $25(OH)D$ levels (Fig. 2B). If the 24-hydroxylase

enzyme (CYP24A1) followed simple Michaelis-Menten kinetics, one might have predicted that

the relationship between plasma levels of $24,25(OH)_2D$ and $25(OH)D$ would have been

described by a hyperbola (Fig. 3A, solid curve) rather than a sigmoid curve (Fig. 3A, dashed

curve). The observed sigmoid curve approaches an asymptote at high levels of $25(OH)D$ – most

likely a reflection of the saturability of the 24-hydroxylase enzyme (CYP24A1). What can

explain the relative underproduction of $24,25(OH)_2D$ at low levels of $25(OH)D$ as compared to

what would have been predicted by simple Michaelis-Menten kinetics? As suggested by others

(18, 23, 28), we hypothesized that expression of 24-hydroxylase enzyme is regulated, with low

24-hydroxylase activity occurring when $25(OH)D$ levels are low and higher 24-hydroxylase

activity when $25(OH)D$ levels are high. We applied mathematical modeling (see Methods

section) to provide quantitative estimates of the relationship between activity of the 24-

hydroxylase enzyme and $25(OH)D$ levels (Fig. 3C). Our model suggests that 24-hydroxylase

activity achieves a maximum when $25(OH)D$ levels exceed 50 ng/mL. In contrast, VitD

deficiency is associated with suppression of 24-hydroxylase activity– achieving a minimum

corresponding to ~90% suppression when $25(OH)D$ levels are less than 10-20 ng/mL. Our

mathematical model provides estimates of 24-hydroxylase activity as a function of $25(OH)D$

levels (Fig. 3C). The data points in Fig. 2A demonstrate substantial "scatter" around the modeled

curve. We hypothesize that the ~3-fold range of inter-individual variation in levels of VitD

binding protein (VDBP) (29) may account for the observed 3.4-fold range of total levels of

$1,25(OH)_2D$ observed in this study, which in turn could account for the observed scatter for data

points in the plot of total levels of $1,25(OH)_2D$ versus total levels of $25(OH)D$ (Fig. 2A).

Interestingly, the modeled curve predicts that levels of $1,25(OH)_2D$ begin to decrease slightly for

levels of $25(OH)D < {\sim}15\text{-}20$ ng/mL. This "fall-off" may possibly be related to the fact that the

model does not account for development of secondary hyperparathyroidism. If the model

specified that low levels of $25(OH)D$ would trigger increased secretion of PTH and resultant

increased 1α-hydroxylation of $25(OH)D$, it is likely that the model would predict constant levels

of $1,25(OH)_2D$ for lower levels of $25(OH)D$.

Validating the model using the goodness of fit

Equation (1) provides a good fit to the observed data as shown by the graph plotting total levels

of $24,25(OH)_2D$ as a function of $25(OH)D$ (Fig. 2B). Goodness of fit is evidenced by the fact

that the sum of the squared errors (SSE) is small relative to the total sum of the squares about the

mean (SST): $SSE/SST = 0.078$ (Table 2).

Moreover, equation (7) correctly predicts that $1,25(OH)_2D$ levels are not correlated with

$25(OH)D$ levels (Fig. 2A). Indeed, the sum of the squared errors (SSE) is approximately equal to

the total sum of the squares about the mean (SST): $SSE/SST = 1.04$ (Table 2). Furthermore, the

value of the ratio of the sum of the squares due to regression (SSR) divided by $SST = 0.094$,

suggesting that a horizontal line described by the following equation: $1,25(OH)_2D = 44.4$ pg/mL

(i.e., the mean level of $1,25(OH)_2D$) provides a good fit for the observed data.

VitD metabolite ratios are better predictive of clinical VitD status

As noted in the literature, ratios of VitD metabolites are relatively independent of inter-individual

variation in VDBP levels (24, 30, 31). For example, the following equations demonstrate that the

ratio of $[1,25(OH)_2D]/[24,25(OH)_2D]$ is independent of VDBP levels:

$\qquad (8)\ [1,25(OH)_2D]_{total} \approx [1,25(OH)_2D]_{free} \times VDBP_{total} \times K_{1,25}$

$(9) \; [24,25(OH)_2D]_{total} \approx [24,25(OH)_2D]_{free} \times VDBP_{total} \times K_{24,25}$

$(10) \; \dfrac{[1,25(OH)_2D]_{total}}{[24,25(OH)_2D]_{total}} \approx \dfrac{[1,25(OH)_2D]_{free}}{[24,25(OH)_2D]_{free}} \times \dfrac{K_{1,25}}{K_{24,25}}$

When the $\dfrac{[1,25(OH)_2D]_{total}}{[24,25(OH)_2D]_{total}}$ ratio is plotted as a function of total levels of 25(OH)D, this

represents a graph of a VDBP-independent variable on the y-axis and a VDBP-dependent

variable on the x-axis (Fig. 4A). In contrast, the graph of $\dfrac{[1,25(OH)_2D]_{total}}{[24,25(OH)_2D]_{total}}$ as a function of

$\dfrac{[25(OH)D]_{total}}{[1,25(OH)_2D]_{total}}$ plots VDBP-independent variables on both axes (Figs. 4B). This approach

minimized the contribution of inter-individual variation in VDBP levels, thereby minimizing

"scatter" of points in the graph (Fig. 4B). When $\dfrac{[1,25(OH)_2D]_{total}}{[24,25(OH)_2D]_{total}}$ was plotted as a function of

$\dfrac{[25(OH)D]_{total}}{[1,25(OH)_2D]_{total}}$, the absolute value of the Spearman correlation coefficient was quite high (ρ=-

0.94; p=10^{-10}) (Fig. 4B). In contrast, the absolute value of the Spearman correlation coefficient

was lower (ρ=-0.83; p=2.2x10^{-6}) when $\dfrac{[1,25(OH)_2D]_{total}}{[24,25(OH)_2D]_{total}}$ was plotted as a function of total levels

of 25(OH)D (Fig. 4A).

Modeling VitD Metabolite Ratios

Tang et al. (23) proposed that the ratio of 1,25(OH)₂D/24,25(OH)₂D provides an improved

assessment of clinical VitD status with a ratio ≥51 suggesting "VitD deficiency" and a ratio of

35-50 suggesting "VitD insufficiency". We applied our mathematical model to predict the shape

of the curve expressing Tang's VitD metabolite ratio (1,25(OH)₂D/1,24(OH)₂D) as a function of

total levels of 25(OH)D. Our modeled curve (Fig. 4A) closely resembles the curve included in

the publication by Tang et al. (23). Based on our modeled curve, the cutoffs proposed by Tang et

al. correspond to total 25(OH)D levels of ~17 ng/mL for "VitD deficiency" and ~21 ng/mL for

"VitD insufficiency".

Furthermore, our mathematical model provides a good fit to the observed data as shown by the

graph plotting total levels of $1,25(OH)_2D/24,25(OH)_2D$ as a function of 25(OH)D (Fig. 4A). Two

other VitD metabolite ratios have been proposed in the literature: $1,25(OH)_2D/25(OH)D$ (32) and

$24,25(OH)_2D/25(OH)D$ (24, 30, 31, 33, 34). Our mathematical model predicts that the

$25(OH)D/1,25(OH)_2D$ ratio (i.e., the reciprocal of the $1,25(OH)_2D/25(OH)D$ ratio proposed in

the literature (32)) is a near-linear function of 25(OH)D levels (Fig. 5A); the graph of the

$24,25(OH)_2D/25(OH)D$ ratio versus 25(OH)D is predicted to be a sigmoid curve (Fig. 5B). The

modeled curves for all three VitD metabolite ratios provide good fits to observed data [SSE/SST

ratios of 0.49-0.52 (Table 2)].

Correlation of relative 24-hydroxylase activity (h) with VitD metabolite ratios

We pooled our data before and after VitD3 supplementation for each of the three VitD

metabolites. We first investigated the correlation of the calculated relative 24-hydroxylase

activity (*h*) with total 25(OH)D levels, which gave a Spearman correlation coefficient of $\rho=0.85$

(p=7E-07) (Fig. 6A). We then evaluated correlations with three VitD metabolite ratios. As

expected, relative 24-hydroxylase activity (*h*) was perfectly correlated with the

$25(OH)D/1,25(OH)_2D$ ratio ($\rho=1$) since this ratio was used in our model to account for the effect

of variation in VDBP (Fig. 6B). While 24-hydroxylase activity (*h*) was highly correlated with the

$1,25(OH)_2D/24,25(OH)_2D$ ratio ($\rho^2=0.94$; p=3E-13) (Fig. 6C), *h* was less well correlated with the

$24,25(OH)_2D/25(OH)$ ratio ($\rho^2=0.67$; p=3E-06) (Fig. 6D).

PTH response to VitD3 supplementation and correlation of PTH with indices of VitD status

Although baseline PTH levels were correlated with baseline total 25(OH)D levels before VitD3

supplementation (R^2=0.08; p=5E-05), the variance in 25(OH)D accounted for only 8% of the

variance in PTH. Furthermore, the slope of the regression line was positive whereas the known

physiology predicts that the slope should be negative (Fig. 7A) with PTH levels being higher

when 25(OH)D levels are lower. Moreover, baseline PTH levels were not significantly

correlated with the baseline $1,25(OH)_2D/24,25(OH)_2D$ ratio (R^2=0.008; p=0.63) (Fig. 7B). Even

in VitD participants who had received VitD3 supplementation, we observed a wide range for

PTH levels (29-85 pg/ml) – suggesting that each participant has an individual setpoint for PTH

levels. Therefore, in order to normalize PTH levels relative to each individual's setpoint, we

defined a PTH index: i.e., the ratio of the PTH level before VitD3 supplementation divided by

the PTH level after VitD3 supplementation. Ten among our 11 participants exhibited PTH

indices between 0.8-1.2, suggesting that their PTH levels were relatively unaffected by VitD3

supplementation. However, one participant had a PTH index of 1.5 – consistent with a diagnosis

of secondary hyperparathyroidism in the VitD deficient state before VitD3 supplementation. The

correlation coefficient was higher when we plotted the PTH index as a function of baseline total

25(OH)D levels prior to receiving VitD3 supplementation (R^2=0.23; p=2E-06) (Fig. 7C)

compared to the correlation of baseline PTH levels with baseline 25(OH)D levels (R^2=0.08;

p=5E-05) (Fig. 7A). Furthermore, the slope was negative for the graph of PTH index as a

function of baseline total 25(OH)D levels as expected based on the known physiology. We also

investigated the correlation of the PTH index with three VitD metabolite ratios. While the

correlation coefficient for the correlation of PTH index with $1,25(OH)_2D/24,25(OH)_2D$ was 0.60

(R^2=0.36; p=0.0002) (Fig. 7D), it was 0.44 for $25(OH)D/1,25(OH)_2D$ ratio (R^2=0.20; p=0.0001)

(Fig. 7E) and 0.35 for the $24,25(OH)_2D/25(OH)D$ ratio (R^2=0.12; p=2E-06) (Fig. 7F). We

conducted a sensitivity analysis by investigating the impact of removing the single participant

whose PTH index was outside the range of 0.8-1.2. When we removed data from that participant,

the correlation coefficient for the PTH index versus the $1,25(OH)_2D/24,25(OH)_2D$ ratio

decreased from 0.60 (p=0.0002) to 0.21 (p=0.0003) (Fig. 7D). Similar decreases were observed

for the values of correlation coefficients for other indices of VitD status (Figs. 7E and 7F).

DISCUSSION

Claude Bernard noted in the 19th century that "*stability of the internal environment (milieu*

intérieur) is a condition for a free and independent life" (10). Later, in the early 20th century,

Walter B. Cannon coined the term "*homeostasis*" to describe mechanisms that maintain the

stability of the *milieu intérieur* (9, 10). Because of the critical importance of Ca^{+2} in many

biological processes, the "*Wisdom of the Body*" (9, 10) has evolved multiple homeostatic

mechanisms to maintain free serum Ca^{+2} levels within a narrow physiological range. Since VitD

plays a critical role in mediating intestinal absorption of dietary Ca^{+2}, homeostatic mechanisms

also maintain free 1,25(OH)$_2$D within narrow physiological ranges. To maintain stable levels of

1,25(OH)$_2$D when VitD availability is scarce, the body has two defense mechanisms: (1) to

increase production of 1,25(OH)$_2$D by increasing PTH-induced 1α-hydroxylation of 25(OH)D

(12, 16, 17) and/or (2) to decrease the metabolic clearance of 1,25(OH)$_2$D by suppressing 24-

hydroxylase – the enzyme which degrades VitD (14, 15). However, as noted in The Endocrine

Society's clinical practice guidelines, VitD deficiency-induced secondary hyperparathyroidism is

associated with adverse effects on bone health: VitD-induced secondary hyperparathyroidism has

an adverse impact on bone health by increasing "*osteoclastic activity thereby creating local foci*

of bone weakness, which causes a generalized decrease in bone mineral density, resulting in

osteopenia and osteoporosis" (17).

Two lines of defense to maintain physiological levels of 1,25(OH)$_2$D

Based on our study's inclusion criteria, all research participants met the Endocrine Society's

criterion for VitD deficiency [i.e., screening 25(OH)D ≤ 20 ng/mL]. While total 25(OH)D and

24,25(OH)$_2$D levels were increased significantly by VitD3 supplementation, total 1,25(OH)$_2$D

did not change. Moreover, levels of PTH were within normal limits at baseline and did not

change when supplements were administered to correct the VitD deficiency. These data are consistent with published evidence suggesting that mild-moderate VitD deficiency may not trigger secondary hyperparathyroidism while secondary hyperparathyroidism is a characteristic feature of severe VitD deficiency [25(OH)D <10-12 ng/mL] (35-37).

The published literature contains many graphs displaying PTH levels as a function of total 25(OH)D (35, 38-41). In general, these graphs depict an increase in mean PTH levels as 25(OH)D levels decrease with an inflection point at total 25(OH)D levels in the range between 20-30 ng/mL. However, individual data points scatter widely above and below the mean values for PTH. If one focuses on mean data, one might conclude that all individuals are gradually becoming increasingly hyperparathyroid as total 25(OH)D decreases. However, detailed analysis of the data suggests an alternative interpretation. If one examines data points corresponding to 25(OH)D levels in the range of 10-20 ng/mL, the vast majority of individual data points span the same range of PTH levels even as 25(OH)D levels decrease. However, the number of outliers (i.e., elevated PTH levels) begins to increase as 25(OH)D levels decrease below ~20 ng/mL. We interpret this observation as suggesting that there is considerable inter-individual variation in the setpoint for developing secondary hyperparathyroidism. When 25(OH)D levels fall below ~10 ng/mL, there is a substantial increase in both the mean level of PTH and the percentage of individuals with secondary hyperparathyroidism. Although the explanation of this phenomenon is not entirely clear, we hypothesize that inter-individual variation in VDBP levels may be an important contributor. Individuals with high VDBP levels are predicted to have lower free 25(OH)D levels at any given level of total 25(OH)D. Thus, such individuals with high VDBP levels would be predicted to develop secondary hyperparathyroidism at higher levels of total 25(OH)D. Accordingly, we hypothesize that VDBP-independent indices of VitD status would

better predict development of secondary hyperparathyroidism. Tang et al provided data

suggesting that the $1,25(OH)_2D/24,25(OH)_2D$ ratio >100 is associated with an increased risk of

elevated PTH level. Our data are consistent with the hypothesis that the

$1,25(OH)_2D/24,25(OH)_2D$ ratio may be better correlated with secondary hyperparathyroidism as

compared to other indices of VitD status such as the total $25(OH)D$ level.

The absence of secondary hyperparathyroidism in our participants with mild-moderate VitD

deficiency inspired us to investigate what other homeostatic mechanisms maintained

$1,25(OH)_2D$ in the normal range. Analysis of our data demonstrated that the correlation between

$25(OH)D$ and $24,25(OH)_2D$ levels was defined by a sigmoid curve rather than a hyperbola.

Based on this observation, we hypothesized that 24-hydroxylase expression is regulated, and we

designed a mathematical model to test our hypothesis. Our model demonstrates that 24-

hydroxylase activity achieves a minimum (~90% suppression) when $25(OH)D$ levels <10-20

ng/mL. Thus, in mild-moderate VitD deficiency, the body suppresses 24-hydroxylation to

preserve VitD from degradation and this mechanism provides the first line of defense against

VitD deficiency. Interestingly, viewed from a different perspective, 24-hydroxylase activity is

induced in response to high levels of $25(OH)D$, which provides a major defense against VitD

toxicity. In the absence of secondary hyperparathyroidism, it is possible that mild-moderate VitD

deficiency may not represent an absolute requirement for treatment with VitD supplements. On

the other hand, recent publications have suggested that $24,25(OH)_2D$ exerts a direct effect to

promote healing of bone fractures (42-44). In other words, whether or not mild-moderate VitD

deficiency increases the risk of bone fracture, it has been proposed that adequate levels of

$24,25(OH)_2D$ may promote healing of bone fractures.

Considerable controversy exists with respect to the overall health impact of VitD status and VitD

supplementation in the general population (45-48). Published literature demonstrates that severe

VitD deficiency triggers secondary hyperparathyroidism, which in turn induces 1α-hydroxylation

– thereby increasing the rate of $1,25(OH)_2D$ biosynthesis (16, 35). Because secondary

hyperparathyroidism is not triggered unless VitD deficiency becomes severe [e.g., 25(OH)D

<10-12 ng/mL], this mechanism provides the second line of defense against VitD deficiency.

Secondary hyperparathyroidism is associated with adverse effects on bone health. This provides

a strong rationale for treatment with VitD supplements. We propose two diagnostic terms to

reflect clinical differences between these two scenarios. "Sub-clinical VitD deficiency" describes

a clinical condition when only the first line of defense (suppression of 24-hydroxylase) has been

triggered. "Overt VitD deficiency" describes a clinical condition when both lines of defense are

triggered (i.e., suppression of 24-hydroxylase plus secondary hyperparathyroidism). This is

consistent with conclusions of a scientific workshop sponsored by the National Kidney

Foundation in 2018, which suggested that in patients with chronic kidney disease, 25(OH)D

levels of <15 ng/mL require VitD treatment and in the range of 15-20 ng/mL, require treatment

only if there is evidence of secondary hyperparathyroidism (22).

Which molecular mechanism(s) mediate homeostatic regulation of 24-hydroxylase activity?

Although expression of the *CYP24A1* gene (the gene encoding 24-hydroxylase enzyme) is

reported to be increased by $1,25(OH)_2D$ and FGF23 but decreased by PTH (49), mean levels of

total $1,25(OH)_2D$, FGF23, and PTH did not change in response to VitD3 supplementation (13).

Taken at face value, these observations suggest that regulation of 24-hydroxylase activity may be

mediated by factors other than levels of $1,25(OH)_2D$, FGF23, or PTH. Nevertheless, it remains

possible that regulation of 24-hydroxylase activity is sensitive to extremely small changes in

levels of 1,25(OH)$_2$D, FGF23, or PTH, which were not captured in our study. Furthermore, all

three hormones exhibit circadian variation (50-52). Since we obtained blood samples at only one

time of day, we cannot exclude the possibility that the relevant biomarker(s) might require

measurements of circulating levels integrated over a 24-hour period. In any case, additional

research will be required to answer this interesting question.

Implications for clinical diagnosis of VitD deficiency

Although the Endocrine Society's clinical practice guidelines recommend a "one-size-fits-all"

approach based on measurements of total levels of 25(OH)D (17), this approach does not

account for the substantial inter-individual variation in levels of VDBP that limits the

applicability of this approach. Whereas the usual clinical assays primarily reflect protein-bound

levels of VitD metabolites, it is the free levels (i.e., not bound to protein) that are biologically

relevant (53). This provides a strong rationale for a *precision diagnostics* approach wherein

diagnostic criteria for VitD deficiency are adjusted for each individual based on that person's

circulating level of VDBP. Other factors may also be relevant: for example, individual setpoints

for PTH secretion and an individual's sensitivity to biological actions of PTH (54). These

considerations raise challenging questions about how best to implement a precision diagnostics

approach to diagnose VitD deficiency and secondary hyperparathyroidism. Others have

suggested the potential value of using a tailored approach to assess VitD status and to guide

decisions about the need for VitD supplementation (55). In clinical endocrinology practice,

deficiency states are frequently diagnosed by documenting the activation of compensatory

homeostatic mechanisms. For example, hypothyroidism is diagnosed by documenting elevated

levels of TSH. Conversely, hyperthyroidism is diagnosed by documenting suppression of TSH

levels (20). By basing diagnoses on whether the body's homeostatic responses have been

triggered, physicians implicitly rely on Cannon's concept of the "*wisdom of the body*" to

diagnose hormonal status. Following these precedents, one might base the diagnosis of VitD

deficiency on documenting the activation of the relevant homeostatic mechanisms – e.g.,

suppression of 24-hydroxylase activity. However, it is challenging to base the diagnosis solely on

measuring total $24,25(OH)_2D$ levels because of the confounding influence of inter-individual

variation in VDBP levels. The observed threefold inter-individual variation in levels of VDBP

(29) is predicted to cause a three fold inter-individual variation in total levels of $24,25(OH)_2D$

even in individuals with identical levels of free $24,25(OH)_2D$. Fortunately, VitD metabolite ratios

are known to be independent of VDBP levels (24). Tang et al. (23) have advocated the use of the

$1,25(OH)_2D/24,25(OH)_2D$ ratio for this purpose. As confirmed by our mathematical model (Fig.

4A), VitD deficiency is associated with a dramatic increase in the $1,25(OH)_2D/24,25(OH)_2D$

ratio as a consequence of the marked suppression of 24-hydroxylase activity induced by VitD

deficiency. By providing an index of the level of 24-hydroxylase activity, the

$1,25(OH)_2D/24,25(OH)_2D$ ratio provides a highly sensitive index of clinical VitD status.

Furthermore, because of the extremely high correlation between the $1,25(OH)_2D/24,25(OH)_2D$

ratio and the $25(OH)D/1,25(OH)_2D$ ratio (Fig. 4B), it seems likely that the

$25(OH)D/1,25(OH)_2D$ ratio might also provide a useful clinical assessment of VitD status. This

latter ratio is based on two widely available assays [25(OH)D and $1,25(OH)_2D$] whereas the

$1,25(OH)_2D/24,25(OH)_2D$ ratio requires an assay for $24,25(OH)_2D$, which is currently less

widely available and more expensive. Different VitD metabolite ratios have been suggested for

assessment of VitD status and some studies have investigated their predictive value for hard

clinical endpoints e.g., risk of bone fracture (31, 33). The $24,25(OH)_2D/25(OH)D$ ratio has

gained attention as a clinically informative substitute for total plasma 25(OH)D for assessment of

VitD status. Furthermore, the scientific workshop sponsored by the National Kidney Foundation

proposed that the $24,25(OH)_2D/25(OH)D$ ratio might be particularly useful in patients with CKD

as a surrogate for activity of 24-hydroxylase, as in this patient population 1α-hydroxylation of

25(OH)D is impaired (22).

Interindividual variation in PTH levels

Even in VitD-replete participants being treated with VitD3 supplements, we observed a wide

range of PTH levels (29-85pg/mL). Furthermore, mean levels of PTH were not significantly

affected by administration of VitD3 supplements in our study (47.5±4.8 pg/mL before and

48.4±5.1 pg/mL after VitD3 supplementation). As suggested by others (56), interindividual

variation in PTH levels may reflect variation in the setpoint for PTH secretion. This creates

major challenges in how to interpret an individual measurement of PTH. We, therefore, assessed

the response of PTH to VitD3 supplementation as an indication of whether a participant

exhibited secondary hyperparathyroidism due to VitD deficiency. While one participant exhibited

a ~34% decrease in PTH level in response to VitD3 supplementation, the other participants did

not exhibit significant suppression of PTH levels in response to VitD3 supplementation. We

compared the performance of various indices of VitD status as predictors of secondary

hyperparathyroidism. Among the indices of VitD status, the $1,25(OH)_2D/24,25(OH)_2D$ ratio was

the most highly correlated with our index of secondary hyperparathyroidism (R^2=0.36;

p=0.0002). However, none of the indices of VitD status accounted for more than 36% of the

variance in our index of secondary hyperparathyroidism – most likely, because only one of our

11 participants had any evidence suggestive of secondary hyperparathyroidism. In contrast, the

$1,25(OH)_2D/24,25(OH)_2D$ ratio was highly correlated (ρ^2=-0.94; p=3E-13) with relative 24-

hydroxylase activity as calculated by our mathematical model – accounting for 94% of the

variance in relative 24-hydroxylase activity. Other indices were less well correlated:

$24,25(OH)_2D/25(OH)D$ (ρ^2=0.67; p=3E-06) and total $25(OH)D$ (ρ^2=0.72; p=7E-07).

We have offered some tentative hypotheses related to the necessity of VitD supplements in overt

VitD deficiency as compared to the possible optional nature of VitD supplements in sub-clinical

VitD deficiency. However, we acknowledge that the present study does not provide sufficient

data to draw rigorous evidence-based conclusions with respect to treatment recommendations.

Our small pilot study is based on biomarker data rather than hard clinical outcomes. Future

research will be required to address these important clinical questions. Nevertheless, we believe

it is valuable to offer hypotheses based on implications derived from consideration of underlying

physiology and pathophysiology.

Acknowledgements

The authors gratefully acknowledge research funding provided by NIDDK and the NIH Office of

Dietary Supplements: R01DK118942, R01DK118942-02S1, and T32DK098107. We are also

grateful to the staff at University of Maryland's Amish Research Clinic and to the members of the

Old Order Amish Community in Lancaster, PA who participated in this clinical trial.

Data Availability

Primary data will be made available upon request to qualified academic investigators for research

purposes under a Data Transfer Agreement to protect research participants' confidential

information.

Table 1. Parameters of the mathematical model.

Model parameters	Definitions
α	A model parameter to facilitate fitting the equation to the observed data
h	Relative 24-hydroxylase activity
$K1$	Michaelis-Menten constant for 1α-hydroxylase with 25(OH)D as substrate
K_{24}	Michaelis-Menten constant for 24-hydroxylase enzyme with 25(OH)D as substrate (to fit hyperbolic curve)
$L_{1,25}$	Analog of Michaelis-Menten constant for 24-hydroxylase enzyme with 1,25(OH)$_2$D as substrate (to fit sigmoid curve)
L_{24}	Analog of Michaelis-Menten constant for 24-hydroxylase enzyme with 25(OH)D as substrate (to fit sigmoid curve)
$m(1,25)$	First order rate constant for metabolic clearance of 1,25(OH)$_2$D
$m(24,25)$	First order rate constant for metabolic clearance of 24,25(OH)$_2$D
$S(1,25)$	1,25(OH)$_2$D concentration
$S(24,25)$	24,25(OH)$_2$D concentration
$S(25)$	25(OH)D concentration
$V1$	Maximal velocity for 1α-hydroxylase with 25(OH)D as substrate
V_{24}	Maximal velocity for 24-hydroxylase with 25(OH)D as substrate (to fit hyperbolic curve)
$W_{1,25}$	Maximal velocity for 24-hydroxylase with 1,25(OH)$_2$D as substrate (to fit sigmoid curve)
W_{24}	Maximal velocity for 24-hydroxylase with 25(OH)D as substrate (to fit sigmoid curve)

570 **Table 2. Goodness of fit for mathematical model equations**. The Table includes metrics for the

571 goodness of fit for the modeling equations for $1,25(OH)_2D$ (Fig. 2A) and $24,25(OH)_2D$ (Fig. 2B)

572 as well as the goodness of fit for modeling of three VitD metabolite ratios (Figs. 4A, 5A, and

573 5B).

	24,25(OH)D	1,25(OH)₂D	1,25(OH)₂D/ 24,25(OH)₂D	25(OH)D/ 1,25(OH)₂D	24,25(OH)₂D/ 25(OH)D
Sum of squares due to regression (SSR) [a]	113	315	809	3.37	0.150
Total sum of squares about mean (SST) [b]	105	3341	849	3.22	0.151
Sum of squared errors (SSE) [c]	8.2	3483	412	1.66	0.079
Ratio of SSE/SST	0.078	1.04	0.49	0.52	0.52
Ratio of SSR/SST	1.08	0.094	0.95	1.05	0.995

[a] $SSR = \sum(\hat{x}_i - \bar{x})^2$

[b] $SST = \sum(x_i - \bar{x})^2$

[c] $SSE = \sum(x_i - \hat{x}_i)^2$

Where x_i represents individual observed total levels of VitD metabolites, $\hat{x}_i$ represents individual
predicted total levels of VitD metabolites, and $\bar{x}$ represents the mean of observed total levels of
VitD metabolites.

Figure 1. Impact of VitD3 supplementation on total levels of VitD metabolites. Healthy

participants (N=11) were recruited based on meeting the Endocrine Society's criterion of VitD

deficiency [25(OH)D ≤20 ng/mL]. Total levels of VitD metabolites were assayed before and after

participants received VitD3 supplements (13): 25(OH)D (panel A), 24,25(OH)$_2$D (panel B), and

1,25(OH)$_2$D (panel C). Data are presented as means ± SEM; p-values were calculated using a

two-tailed t-test for paired data.

Figure 2. Total levels of 1,25(OH)₂D and 24,25(OH)₂D as a function of total levels of

25(OH)D. Panels A and B present pooled data for individual participants when they were VitD

deficient (gray circles) and after they received VitD3 supplements (black circles). 1,25(OH)₂D

(panel A) and 24,25(OH)₂D (panel B) are plotted as a function of total levels of 25(OH)D. The

text box in panel B presents the Spearman correlation coefficient (ρ). The curves represent the

equations derived from our mathematical model: equation (1) in Panel A and equation (7) in

Panel B. Values of parameters for Equation (1): W_{24}=8 ng/mL; L_{24}=40 ng/mL; and α=0.1. Values

for parameters for Equation (7): $W_{1,25}$=40 ng/mL; $L_{1,25}$=60 ng/mL; V_1=40; K=60 ng/mL; α=0.1;

and $m_{1,25}$=1.

Figure 3. Assumptions underlying mathematical model: regulation of 24-hydroxylase

activity in response to clinical VitD status. Panel A depicts curves corresponding to equations

(1) and (2) [sigmoid and hyperbola, respectively]. Panel B depicts a family of hyperbolas

[equation (2)] corresponding to varying degrees of induction from 10-100% of maximal

induction of 24-hydroxylase activity. Panel C depicts equation (3), which is the fractional

induction of 24-hydroxylase activity relative to the maximal level of induction as a function of

25(OH)D. Values of parameters for Equation (1): $W_{24}=8$ ng/mL; $L_{24}=40$ ng/mL; and $\alpha=.0.1$.

Values for parameters for Equation (2): $V_{24}=10$ and $K_{24}=20$ ng/mL. Values of parameters for

Equation (3) m(24,25)=1; other parameters the same as for Equations (1) and (2).

Figure 4. The 1,25(OH)₂D/24,25(OH)D and 25(OH)D/1,25(OH)₂D ratios reflect clinical

VitD status. The graphs summarize data from individual participants when they were VitD

deficient (gray circles) and after they received VitD3 supplements (black circles). Panel A depicts

the 1,25(OH)₂D/24,25(OH)₂D ratio as a function of total 25(OH)D. The modeled curve was

calculated as the ratio of modeled values for 1,25(OH)₂D [equation (7)] divided by modeled

values of 24,25(OH)₂D [equation (1)]. Panel B depicts 1,25(OH)₂D/24,25(OH)₂D ratio as a

function of 25(OH)D/1,25(OH)₂D ratio. The fitted curves were calculated by GraphPad Prism

software. Text boxes indicate Spearman correlation coefficients and p-values for the correlations.

Figure 5. VitD metabolite ratios [25(OH)D/1,25(OH)$_2$D and 24,25(OH)$_2$D/25(OH)D] as a

function of the total levels of 25(OH)D. The graphs summarize data from individual

participants when they were VitD deficient (gray circles) and after they received VitD3

supplements (black circles). Panel A depicts the 25(OH)D/1,25(OH)$_2$D ratio as a function of total

25(OH)D. The modeled curve was calculated as a linear regression using GraphPad Prism

software. Panel B depicts 24,25(OH)$_2$D/25(OH)D ratio as a function of 25(OH)D. The modeled

curve was calculated as modeled values for 24,25(OH)$_2$D [equation (1)] divided by assumed

values of 25(OH)D.

 Figure 6. Correlation between relative 24-hydroxylase activity (*h*) and indices of VitD

status. Panels A-D present pooled data when participants were VitD deficient (gray circles) and

after they received VitD3 supplementation (black circles). The text boxes below the panels

present two Spearman correlation coefficients and two p-values. The first bullet points

correspond to the correlation between 24-hydroxylase and each of the VitD status indices at

baseline before participants received VitD3 supplementation. The second bullet points

correspond to the correlation between 24-hydroxylase and each of the VitD status indices based

on the pooled data (both before and after VitD3 supplementation). The curves in the graphs were

based on modeling of the pooled data.

Figure 7. Correlation between PTH and different indices of VitD status. Panels A and B

depict correlations of baseline PTH levels with baseline total 25(OH)D (panel A) or baseline

$1,25(OH)_2D/24,25(OH)_2D$ ratio (panel B) before participants received VitD3 supplementation.

Panel C depicts the correlation between the PTH index (PTH level before VitD3 supplementation

divided by PTH level after VitD3 supplementation) and baseline total 25(OH)D. Panels D, E, and

F depict correlations between the PTH index and other indices of VitD status:

$1,25(OH)_2D/24,25(OH)_2D$ ratio (panel D), $25(OH)D/1,25(OH)_2D$ ratio (panel E), and

$24,25(OH)_2D/25(OH)D$ ratio (panel F). The solid black lines correspond to least-squares fits for

all 11 data points. Gray dotted lines in panels C-F correspond to a sensitivity analysis conducted

by removing the participant who had the highest $1,25(OH)_2D/24,25(OH)_2D$ ratio and PTH index.

That participant is shown by a gray square in the panels C-F. The text boxes below panels C-F

present equations and p-values corresponding to the gray dotted lines.

REFERENCES:

1. Christakos S, Dhawan P, Porta A, Mady LJ, and Seth T. Vitamin D and intestinal calcium absorption. *Mol Cell Endocrinol.* 2011;347(1-2):25-9.

2. Fleet JC. Vitamin D-Mediated Regulation of Intestinal Calcium Absorption. *Nutrients.* 2022;14(16).

3. Christakos S, Li S, De La Cruz J, Shroyer NF, Criss ZK, Verzi MP, et al. Vitamin D and the intestine: Review and update. *J Steroid Biochem Mol Biol.* 2020;196:105501.

4. Fleet JC. The role of vitamin D in the endocrinology controlling calcium homeostasis. *Mol Cell Endocrinol.* 2017;453:36-45.

5. Chick HD, E.G.; Hume, M.; Mackay, H.M.M.; Smith, H.H.; Wimberger, H. The aetiology of rickets in infants: Prophylactic and curative observations at the Vienna University Kinderklinik. *The Lancet.* 1922:7-11.

6. Rajakumar K. Vitamin D, cod-liver oil, sunlight, and rickets: a historical perspective. *Pediatrics.* 2003;112(2):e132-5.

7. Miller WL, and Imel EA. Rickets, Vitamin D, and Ca/P Metabolism. *Horm Res Paediatr.* 2022;95(6):579-92.

8. Bikle DD. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al. eds. *Endotext.* South Dartmouth (MA): MDText.com, Inc. Copyright © 2000-2023, MDText.com, Inc.; 2000.

9. Cannon WB. *The wisdom of the body.* Norton and Company Limited, W. W.; 1963.

10. Davies KJ. Adaptive homeostasis. *Mol Aspects Med.* 2016;49:1-7.

11. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. *Ann Epidemiol.* 2009;19(2):73-8.

670   12.   Young K, Beggs MR, Grimbly C, and Alexander RT. Regulation of 1 and 24

671   hydroxylation of vitamin D metabolites in the proximal tubule. *Exp Biol Med*

672   *(Maywood)*. 2022;247(13):1103-11.

673   13.   Shahidzadeh Yazdi Z, Streeten EA, Whitlatch HB, Montasser ME, Beitelshees AL, and

674   Taylor SI. Vitamin D deficiency increases vulnerability to canagliflozin-induced adverse

675   effects on 1,25-dihydroxyvitamin D and PTH. *J Clin Endocrinol Metab*. 2023.

676   14.   Jones G, Strugnell SA, and DeLuca HF. Current understanding of the molecular actions

677   of vitamin D. *Physiol Rev.* 1998;78(4):1193-231.

678   15.   Jones G, Prosser DE, and Kaufmann M. 25-Hydroxyvitamin D-24-hydroxylase

679   (CYP24A1): its important role in the degradation of vitamin D. *Arch Biochem Biophys.*

680   2012;523(1):9-18.

681   16.   Brenza HL, Kimmel-Jehan C, Jehan F, Shinki T, Wakino S, Anazawa H, et al. Parathyroid

682   hormone activation of the 25-hydroxyvitamin D3-1alpha-hydroxylase gene promoter.

683   *Proc Natl Acad Sci U S A.* 1998;95(4):1387-91.

684   17.   Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et

685   al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society

686   clinical practice guideline. *J Clin Endocrinol Metab.* 2011;96(7):1911-30.

687   18.   Tanaka Y, and DeLuca HF. Stimulation of 24,25-dihydroxyvitamin D3 production by

688   1,25-dihydroxyvitamin D3. *Science.* 1974;183(130):1198-200.

689   19.   Tahaka Y, Lorenc RS, and DeLuca HF. The role of 1,25-dihydroxyvitamin D3 and

690   parathyroid hormone in the regulation of chick renal 25-hydroxyvitamin D3-24-

691   hydroxylase. *Arch Biochem Biophys.* 1975;171(2):521-6.

692   20.   Ladenson PW. Diseases of the thyroid gland. *Clin Endocrinol Metab.* 1985;14(1):145-73.

693   21.   Raff H, and Carroll T. Cushing's syndrome: from physiological principles to diagnosis
694   and clinical care. *J Physiol.* 2015;593(3):493-506.

695   22.   Melamed ML, Chonchol M, Gutiérrez OM, Kalantar-Zadeh K, Kendrick J, Norris K, et
696   al. The Role of Vitamin D in CKD Stages 3 to 4: Report of a Scientific Workshop
697   Sponsored by the National Kidney Foundation. *Am J Kidney Dis.* 2018;72(6):834-45.

698   23.   Tang JCY, Jackson S, Walsh NP, Greeves J, and Fraser WD. The dynamic relationships
699   between the active and catabolic vitamin D metabolites, their ratios, and associations with
700   PTH. *Sci Rep.* 2019;9(1):6974.

701   24.   Ginsberg C, Hoofnagle AN, Katz R, Becker JO, Kritchevsky SB, Shlipak MG, et al. The
702   Vitamin D Metabolite Ratio Is Independent of Vitamin D Binding Protein Concentration.
703   *Clin Chem.* 2021;67(2):385-93.

704   25.   Biancuzzo RM, Clarke N, Reitz RE, Travison TG, and Holick MF. Serum concentrations
705   of 1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 in response to vitamin D2
706   and vitamin D3 supplementation. *J Clin Endocrinol Metab.* 2013;98(3):973-9.

707   26.   Schlingmann KP, Kaufmann M, Weber S, Irwin A, Goos C, John U, et al. Mutations in
708   CYP24A1 and idiopathic infantile hypercalcemia. *N Engl J Med.* 2011;365(5):410-21.

709   27.   Streeten EA, Zarbalian K, and Damcott CM. CYP24A1 mutations in idiopathic infantile
710   hypercalcemia. *N Engl J Med.* 2011;365(18):1741-2; author reply 2-3.

711   28.   Batacchi Z, Robinson-Cohen C, Hoofnagle AN, Isakova T, Kestenbaum B, Martin KJ, et
712   al. Effects of Vitamin D(2) Supplementation on Vitamin D(3) Metabolism in Health and
713   CKD. *Clin J Am Soc Nephrol.* 2017;12(9):1498-506.

714   29.   Robinson-Cohen C, Zelnick LR, Hoofnagle AN, Lutsey PL, Burke G, Michos ED, et al.
715   Associations of Vitamin D-Binding Globulin and Bioavailable Vitamin D Concentrations

With Coronary Heart Disease Events: The Multi-Ethnic Study of Atherosclerosis (MESA). *J Clin Endocrinol Metab.* 2017;102(8):3075-84.

30. Ahmed LHM, Butler AE, Dargham SR, Latif A, Chidiac OM, Atkin SL, et al. Vitamin D(3) metabolite ratio as an indicator of vitamin D status and its association with diabetes complications. *BMC Endocr Disord.* 2020;20(1):161.

31. Ginsberg C, Hoofnagle AN, Katz R, Hughes-Austin J, Miller LM, Becker JO, et al. The Vitamin D Metabolite Ratio Is Associated With Changes in Bone Density and Fracture Risk in Older Adults. *J Bone Miner Res.* 2021;36(12):2343-50.

32. Meng L, Su C, Shapses SA, and Wang X. Total and free vitamin D metabolites in patients with primary hyperparathyroidism. *J Endocrinol Invest.* 2022;45(2):301-7.

33. Bansal N, Katz R, Appel L, Denburg M, Feldman H, Go AS, et al. Vitamin D Metabolic Ratio and Risks of Death and CKD Progression. *Kidney Int Rep.* 2019;4(11):1598-607.

34. Ginsberg C, Katz R, de Boer IH, Kestenbaum BR, Chonchol M, Shlipak MG, et al. The 24,25 to 25-hydroxyvitamin D ratio and fracture risk in older adults: The cardiovascular health study. *Bone.* 2018;107:124-30.

35. Jesudason D, Need AG, Horowitz M, O'Loughlin PD, Morris HA, and Nordin BE. Relationship between serum 25-hydroxyvitamin D and bone resorption markers in vitamin D insufficiency. *Bone.* 2002;31(5):626-30.

36. Jones G. 100 YEARS OF VITAMIN D: Historical aspects of vitamin D. *Endocr Connect.* 2022;11(4).

37. Rosen CJ, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, et al. IOM committee members respond to Endocrine Society vitamin D guideline. *J Clin Endocrinol Metab.* 2012;97(4):1146-52.

739   38.   Mendes MM, Hart KH, Lanham-New SA, and Botelho PB. Suppression of Parathyroid

740   Hormone as a Proxy for Optimal Vitamin D Status: Further Analysis of Two Parallel

741   Studies in Opposite Latitudes. *Nutrients.* 2020;12(4).

742   39.   Looker AC, and Gunter EW. Hypovitaminosis D in medical inpatients. *N Engl J Med.*

743   1998;339(5):344-5; author reply 5-6.

744   40.   Shah S, Chiang C, Sikaris K, Lu Z, Bui M, Zebaze R, et al. Serum 25-Hydroxyvitamin D

745   Insufficiency in Search of a Bone Disease. *J Clin Endocrinol Metab.* 2017;102(7):2321-

746   8.

747   41.   Gallagher JC, Jindal PS, and Smith LM. Vitamin D supplementation in young White and

748   African American women. *J Bone Miner Res.* 2014;29(1):173-81.

749   42.   Demay MB. The good and the bad of vitamin D inactivation. *J Clin Invest.*

750   2018;128(9):3736-8.

751   43.   Martineau C, Kaufmann M, Arabian A, Jones G, and St-Arnaud R. Preclinical safety and

752   efficacy of 24R,25-dihydroxyvitamin D(3) or lactosylceramide treatment to enhance

753   fracture repair. *J Orthop Translat.* 2020;23:77-88.

754   44.   Martineau C, Naja RP, Husseini A, Hamade B, Kaufmann M, Akhouayri O, et al. Optimal

755   bone fracture repair requires 24R,25-dihydroxyvitamin D3 and its effector molecule

756   FAM57B2. *J Clin Invest.* 2018;128(8):3546-57.

757   45.   Bouillon R, Manousaki D, Rosen C, Trajanoska K, Rivadeneira F, and Richards JB. The

758   health effects of vitamin D supplementation: evidence from human studies. *Nat Rev*

759   *Endocrinol.* 2022;18(2):96-110.

760   46.   Cummings SR, and Rosen C. VITAL Findings - A Decisive Verdict on Vitamin D

761   Supplementation. *N Engl J Med.* 2022;387(4):368-70.

762   47.   LeBoff MS, Chou SH, Ratliff KA, Cook NR, Khurana B, Kim E, et al. Supplemental

763   Vitamin D and Incident Fractures in Midlife and Older Adults. *N Engl J Med.*

764   2022;387(4):299-309.

765   48.   Pfotenhauer KM, and Shubrook JH. Vitamin D Deficiency, Its Role in Health and

766   Disease, and Current Supplementation Recommendations. *J Am Osteopath Assoc.*

767   2017;117(5):301-5.

768   49.   Meyer MB, and Pike JW. Mechanistic homeostasis of vitamin D metabolism in the

769   kidney through reciprocal modulation of Cyp27b1 and Cyp24a1 expression. *J Steroid*

770   *Biochem Mol Biol.* 2020;196:105500.

771   50.   Blau JE, Bauman V, Conway EM, Piaggi P, Walter MF, Wright EC, et al. Canagliflozin

772   triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a

773   randomized crossover study. *JCI Insight.* 2018;3(8).

774   51.   el-Hajj Fuleihan G, Klerman EB, Brown EN, Choe Y, Brown EM, and Czeisler CA. The

775   parathyroid hormone circadian rhythm is truly endogenous--a general clinical research

776   center study. *J Clin Endocrinol Metab.* 1997;82(1):281-6.

777   52.   Kawai M, Kinoshita S, Shimba S, Ozono K, and Michigami T. Sympathetic activation

778   induces skeletal Fgf23 expression in a circadian rhythm-dependent manner. *J Biol Chem.*

779   2014;289(3):1457-66.

780   53.   Bikle DD. The Free Hormone Hypothesis: When, Why, and How to Measure the Free

781   Hormone Levels to Assess Vitamin D, Thyroid, Sex Hormone, and Cortisol Status. *JBMR*

782   *Plus.* 2021;5(1):e10418.

783   54.   Lemoine S, Figueres L, Bacchetta J, Frey S, and Dubourg L. Calcium homeostasis and

784   hyperparathyroidism: Nephrologic and endocrinologic points of view. *Ann Endocrinol*

785   *(Paris).* 2022;83(4):237-43.

786   55.   Bilezikian JP, Formenti AM, Adler RA, Binkley N, Bouillon R, Lazaretti-Castro M, et al.

787   Vitamin D: Dosing, levels, form, and route of administration: Does one approach fit all?

788   *Rev Endocr Metab Disord.* 2021;22(4):1201-18.

789   56.   Robinson-Cohen C, Lutsey PL, Kleber ME, Nielson CM, Mitchell BD, Bis JC, et al.

790   Genetic Variants Associated with Circulating Parathyroid Hormone. *J Am Soc Nephrol.*

791   2017;28(5):1553-65.

792